The Asia Pacific Large Molecule Drug Substance CDMO Market should witness market growth of 9.1% CAGR during the forecast period (2022-2028).
The demand for biologics and generic drugs is increasing exponentially, which has also propelled high competition in the pharmaceutical industry. The benefit of increased competition resulted in increased the pace of technological innovations increased. The downside to this was rising cost constraints.
As a result, the pharmaceutical industry’s dependence on CDMOs has increased to aid in overcoming many limitations. Through CDMOs, the pharmaceutical industry can progress its clinical candidate development, candidate registration, market authorization, and manufacturing. Many companies in the industry have also revisited their troublesome production operations to manage company assets and resources effectively.
This has helped the companies to regulate their finances. Additionally, CDMOs are able to provide cost-effective manufacturing and development services. Therefore, outsourcing development and manufacturing processes to a CDMO helps pharmaceutical companies increase their technical abilities without the restriction of rethinking equipment prices.
In this region, CDMOs providing services for the processing and development of biologics is growing. This growth is primarily influenced by the region’s massive and growing elderly proportion, who are demanding for better performing medicines. Additionally, in comparison to western regions, the affordability of biopharmaceuticals is high the Asia Pacific region. The emergence of biosimilars, which are low-cost generic variants of biologics, are driving up the investments for the regional CDMOs.
The China market dominated the Asia Pacific Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1, 965.8 million by 2028. The Japan market is estimated to grow a CAGR of 8.5% during (2022-2028). Additionally, The India market would experience a CAGR of 9.8% during (2022-2028).
Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.
The demand for biologics and generic drugs is increasing exponentially, which has also propelled high competition in the pharmaceutical industry. The benefit of increased competition resulted in increased the pace of technological innovations increased. The downside to this was rising cost constraints.
As a result, the pharmaceutical industry’s dependence on CDMOs has increased to aid in overcoming many limitations. Through CDMOs, the pharmaceutical industry can progress its clinical candidate development, candidate registration, market authorization, and manufacturing. Many companies in the industry have also revisited their troublesome production operations to manage company assets and resources effectively.
This has helped the companies to regulate their finances. Additionally, CDMOs are able to provide cost-effective manufacturing and development services. Therefore, outsourcing development and manufacturing processes to a CDMO helps pharmaceutical companies increase their technical abilities without the restriction of rethinking equipment prices.
In this region, CDMOs providing services for the processing and development of biologics is growing. This growth is primarily influenced by the region’s massive and growing elderly proportion, who are demanding for better performing medicines. Additionally, in comparison to western regions, the affordability of biopharmaceuticals is high the Asia Pacific region. The emergence of biosimilars, which are low-cost generic variants of biologics, are driving up the investments for the regional CDMOs.
The China market dominated the Asia Pacific Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1, 965.8 million by 2028. The Japan market is estimated to grow a CAGR of 8.5% during (2022-2028). Additionally, The India market would experience a CAGR of 9.8% during (2022-2028).
Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.
Scope of the Study
By Application
- Mammalian
- Microbial
- Others
By Service
- Contract Manufacturing
- Commercial
- Clinical
- Contract Development
- Cell Line Development
- Process Development
By End-user
- Biotech Companies
- CRO
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Eurofins Scientific SE
- WuXi Biologics (Cayman), Inc
- Catalent, Inc.
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
- Samsung Biologics Co., Ltd. (Samsung Group)
- Rentschler Biopharma SE
- AGC Biologics, Inc. (AGC, Inc.)
- Recipharm AB (EQT AB)
- Siegfried Holding AG
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Large Molecule Drug Substance CDMO Market, by Application
1.4.2 Asia Pacific Large Molecule Drug Substance CDMO Market, by Service
1.4.3 Asia Pacific Large Molecule Drug Substance CDMO Market, by End-user
1.4.4 Asia Pacific Large Molecule Drug Substance CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2019, Apr- 2022, Oct) Leading Players
3.3.3 Key Strategic Move: (Acquisitions and Mergers : 2018, Oct - 2022, Aug) Leading Players
Chapter 4. Asia Pacific Large Molecule Drug Substance CDMO Market by Application
4.1 Asia Pacific Mammalian Market by Country
4.2 Asia Pacific Microbial Market by Country
4.3 Asia Pacific Other Application Market by Country
Chapter 5. Asia Pacific Large Molecule Drug Substance CDMO Market by Service
5.1 Asia Pacific Contract Manufacturing Market by Country
5.2 Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
5.2.1 Asia Pacific Commercial Market by Country
5.2.2 Asia Pacific Clinical Market by Country
5.3 Asia Pacific Contract Development Market by Country
5.4 Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Development Type
5.4.1 Asia Pacific Cell Line Development Market by Country
5.4.2 Asia Pacific Process Development Market by Country
Chapter 6. Asia Pacific Large Molecule Drug Substance CDMO Market by End-user
6.1 Asia Pacific Biotech Companies Market by Country
6.2 Asia Pacific CRO Market by Country
6.3 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Large Molecule Drug Substance CDMO Market by Country
7.1 China Large Molecule Drug Substance CDMO Market
7.1.1 China Large Molecule Drug Substance CDMO Market by Application
7.1.2 China Large Molecule Drug Substance CDMO Market by Service
7.1.2.1 China Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.1.2.2 China Large Molecule Drug Substance CDMO Market by Contract Development Type
7.1.3 China Large Molecule Drug Substance CDMO Market by End-user
7.2 Japan Large Molecule Drug Substance CDMO Market
7.2.1 Japan Large Molecule Drug Substance CDMO Market by Application
7.2.2 Japan Large Molecule Drug Substance CDMO Market by Service
7.2.2.1 Japan Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.2.2.2 Japan Large Molecule Drug Substance CDMO Market by Contract Development Type
7.2.3 Japan Large Molecule Drug Substance CDMO Market by End-user
7.3 India Large Molecule Drug Substance CDMO Market
7.3.1 India Large Molecule Drug Substance CDMO Market by Application
7.3.2 India Large Molecule Drug Substance CDMO Market by Service
7.3.2.1 India Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.3.2.2 India Large Molecule Drug Substance CDMO Market by Contract Development Type
7.3.3 India Large Molecule Drug Substance CDMO Market by End-user
7.4 South Korea Large Molecule Drug Substance CDMO Market
7.4.1 South Korea Large Molecule Drug Substance CDMO Market by Application
7.4.2 South Korea Large Molecule Drug Substance CDMO Market by Service
7.4.2.1 South Korea Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.4.2.2 South Korea Large Molecule Drug Substance CDMO Market by Contract Development Type
7.4.3 South Korea Large Molecule Drug Substance CDMO Market by End-user
7.5 Singapore Large Molecule Drug Substance CDMO Market
7.5.1 Singapore Large Molecule Drug Substance CDMO Market by Application
7.5.2 Singapore Large Molecule Drug Substance CDMO Market by Service
7.5.2.1 Singapore Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.5.2.2 Singapore Large Molecule Drug Substance CDMO Market by Contract Development Type
7.5.3 Singapore Large Molecule Drug Substance CDMO Market by End-user
7.6 Malaysia Large Molecule Drug Substance CDMO Market
7.6.1 Malaysia Large Molecule Drug Substance CDMO Market by Application
7.6.2 Malaysia Large Molecule Drug Substance CDMO Market by Service
7.6.2.1 Malaysia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.6.2.2 Malaysia Large Molecule Drug Substance CDMO Market by Contract Development Type
7.6.3 Malaysia Large Molecule Drug Substance CDMO Market by End-user
7.7 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market
7.7.1 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Application
7.7.2 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Service
7.7.2.1 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.7.2.2 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Development Type
7.7.3 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by End-user
Chapter 8. Company Profiles
8.1 Teledyne FLIR LLC (Teledyne Technologies Incorporated)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations and Agreements:
8.1.4.2 Product Launches and Product Expansions:
8.1.5 SWOT Analysis
8.2 Hikvision Digital Technology Co., Ltd., (China Electronics Technology Group Corporation)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.4.2 Product Launches and Product Expansions:
8.3 Axis Communications AB (Canon, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Product Launches and Product Expansions:
8.4 Bosch Security Systems GmbH (Robert Bosch GmbH)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.5 Avigilon Corporation (Motorola Solutions)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional & Segmental Analysis
8.5.4 Research & Development Expenses
8.6 Hanwha Techwin Co., Ltd. (Hanwha Group)
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Partnerships, Collaborations, and Agreements:
8.6.2.2 Product Launches and Product Expansions:
8.7 Zhejiang Dahua Technology Co., Ltd.
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Product Launches and Product Expansions:
8.8 Zhejiang Uniview Technologies Co., Ltd. (Hangzhou Jiaozhi Technology Co., Ltd.)
8.8.1 Company Overview
8.8.2 Recent strategies and developments:
8.8.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- Eurofins Scientific SE
- WuXi Biologics (Cayman), Inc
- Catalent, Inc.
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
- Samsung Biologics Co., Ltd. (Samsung Group)
- Rentschler Biopharma SE
- AGC Biologics, Inc. (AGC, Inc.)
- Recipharm AB (EQT AB)
- Siegfried Holding AG
Methodology
LOADING...
